The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Open accessAbstract
In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous incretin hormones (gastric inhibitory peptide [GIP] and glucagon-like peptide 1 [GLP-1] [7-36 amide]) in nine type-2 diabetic patients (fasting plasma glucose 7.8 mmol/liter; hemoglobin A1c 6.3 +/- 0.6%) and in nine age- and weight-matched normal subjects. Synthetic human GIP (0.8 and 2.4 pmol/kg.min over 1 h each), GLP-1 [7-36 amide] (0.4 and 1.2 pmol/kg.min over 1 h each), and placebo were administered under hyperglycemic clamp conditions (8.75 mmol/liter) in separate experiments. Plasma GIP and GLP-1 [7-36 amide] concentrations (radioimmunoassay) were comparable to those after oral glucose with the low, and clearly supraphysiological with the high infusion rates. Both GIP and GLP-1 [7-36 amide] dose-dependently augmented insulin secretion (insulin, C-peptide) in both groups (P < 0.05). With GIP, the maximum effect in type-2 diabetic patients was significantly lower (by 54%; P < 0.05) than in normal subjects. With GLP-1 [7-36 amide] type-2 diabetic patients reached 71% of the increments in C-peptide of normal subjects (difference not significant). Glucagon was lowered during hyperglycemic clamps in normal subjects, but not in type-2 diabetic patients, and further by GLP-1 [7-36 amide] in both groups (P < 0.05), but not by GIP. In conclusion, in mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity. It also lowers glucagon concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In individuals with T2DM, there is a decrease in the incretin effect which primarily attributed to the diminished effects of gastric inhibitory polypeptide (GIP).9”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [137]
Experimental — accuracy not yet measuredIn the citing paper
“which is not observed in the set of T2D where the endocrine pancreas ceases responsiveness to GIP but remains responsive to GLP-1, explaining the reduced/absent incretin effect of GIP in T2D [22,23].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [23]
In the citing paper
“However, GIP action is lost in T2D and even infusions of GIP that result in supraphysiological concentrations fail to elicit a significant insulin secretory response in T2D patients.160”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [160]
In the citing paper
“in type 2 diabetes, a markedly attenuated insulinotropic action of GIP (66) and, in some cases, attenuated secretion of GLP-1 (67), contribute to an impairment of postprandial insulin secretion, so that the latter is insufficient to maintain euglycaemia.”
From Gut mechanisms linking intestinal sweet sensing to glycemic control (2018) · cites this paper as [66]
In the citing paper
“In the setting of GIP/GLP-1 receptor agonist (dual agonism), GLP-1 quells the potential glucagon-stimulatory effects of GIP (64) and also (re)sensitizes beta cells to GIP's incretin effects (57), all while potentially enhancing GIP's beneficial effects on weight regulation mechanisms.”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“It remained in the shadow of GLP-1, partly because GIP-stimulated insulin secretion is significantly blunted in individuals with T2D (56); notably, responsiveness can be restored by mitigating hyperglycemia (57).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“GIP has been found to stimulate glucagon secretion, particularly at lower glucose values [14], whereas GLP-1 suppresses glucagon release and, consequently, reduces hepatic glucose production [15].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationPlasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 889
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [45]45. Creutzfeldt, W., and U. R. Folsch. 1983. Delaying Absorption as a Thera- peutic Principle in Metabolic Disease. Georg-Thieme-Verlag, Stuttgart.
Cited by
Sorted by citations
Items 301–400 of 1,003
Mohammad, S., Patel, R. T., Bruno, J., Panhwar, M. S., Wen, J., & McGraw, T. E. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00256-14 · Cited by 104
GLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110
Ghrelin Is a Novel Regulator of GLP-1 Secretion
Gagnon, J., Baggio, L. L., Drucker, D. J., & Brubaker, P. L. (2014) · Diabetes · doi:10.2337/db14-1176 · Cited by 110
Godinho, R., Mega, C., Teixeira‐Lemos, E., Carvalho, E., Teixeira, F. J., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 111
Parkes, D. G., Mace, K. F., & TRAUTMANN, M. E. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.741580 · Cited by 114
Do we know the true mechanism of action of the DPP ‐4 inhibitors?
Andersen, E. S., Deacon, C. F., & Holst, J. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13018 · Cited by 114
Self-citationDipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug
IDRIS, I. R., & Donnelly, R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00705.x · Cited by 113
Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 108
Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D’Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 107
Incretin-Based Therapies: Review of Current Clinical Trial Data
Peters, A. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.007 · Cited by 107
Neural regulation of glucagon-like peptide-1 secretion in pigs
Hansen, L., Lampert, S., Mineo, H., & Holst, J. J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00197.2004 · Cited by 103
Self-citationThe GLP-1 journey: from discovery science to therapeutic impact
Drucker, D. J. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175634 · Cited by 117
Therapeutic potential for GIP receptor agonists and antagonists
Irwin, N., & Flatt, P. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.001 · Cited by 105
Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum
Ritzel, U., Fromme, A., Ottleben, M., Leonhardt, U., & Ramadori, G. P. (1997) · Acta Diabetologica · doi:10.1007/s005920050059 · Cited by 106
The Incretin Approach for Diabetes Treatment
Holst, J. J., & Ørskov, C. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s197 · Cited by 110
Self-citationGlucagon‐Like Peptide‐1: Regulation of Insulin Secretion and Therapeutic Potential
Gromada, J., Brock, B., Schmitz, O., & Rorsman, P. (2004) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2004.t01-1-pto950502.x · Cited by 103
Deane, A. M., Chapman, M. J., Fraser, R. J. L., Summers, M. J., Zaknic, A. V., Storey, J. P., Jones, K. L., Rayner, C. K., & Horowitz, M. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d9d87a · Cited by 104
Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter
Larsen, P. J., & Holst, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.026 · Cited by 108
Self-citationIrwin, N., McClean, P. L., O'Harte, F. P. M., Gault, V. A., Harriott, P., & Flatt, P. R. (2007) · Diabetologia · doi:10.1007/s00125-007-0692-2 · Cited by 102
Glucagon‐like Peptide‐2 and the Regulation of Intestinal Growth and Function
Brubaker, P. L. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170055 · Cited by 132
Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes
Muscelli, E., Casolaro, A., Gastaldelli, A., Mari, A., Seghieri, G., Astiarraga, B., Chen, Y., Alba, M., Holst, J. J., & Ferrannini, E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1205 · Cited by 102
Self-citationEid, H. M., Wright, M. L., Kumar, N. V. A., Qawasmeh, A., Hassan, S. T. S., Mocan, A., Nabavi, S. M., Rastrelli, L., Atanasov, A. G., & Haddad, P. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00387 · Cited by 110
Gasbjerg, L. S., Christensen, M., Hartmann, B., Lanng, A. R., Sparre‐Ulrich, A. H., Gabe, M. B. N., Dela, F., Vilsbøll, T., Holst, J. J., ROSENKILDE, M. M., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4447-4 · Cited by 98
Self-citationGLP‐1 agonists for obesity and type 2 diabetes in children: Systematic review and meta‐analysis
Chadda, K. R., Cheng, T. S., & Ong, K. K. (2020) · Obesity Reviews · doi:10.1111/obr.13177 · Cited by 107
Mingrone, G., Nolfe, G., Gissey, G. C., Iaconelli, A., Leccesi, L., Guidone, C., Nanni, G., & Holst, J. J. (2009) · Diabetologia · doi:10.1007/s00125-009-1288-9 · Cited by 102
Self-citationPreserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus
Hare, K. J., Knop, F. K., Asmar, M., Madsbad, S., Deacon, C. F., Holst, J. J., & Vilsbøll, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0921 · Cited by 103
Self-citationZarrinpar, A., & Loomba, R. S. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12084 · Cited by 104
Widenmaier, S. B., Kim, S. J., Yang, G. K., Reyes, T. D. L., Nian, C., Asadi, A., Seino, Y., Kieffer, T. J., Kwok, Y. N., & McIntosh, C. H. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009590 · Cited by 103
Is glucagon-like peptide 1 an incretin hormone?
Nauck, M. A. (1999) · Diabetologia · doi:10.1007/s001250051165 · Cited by 102
Self-citationGLP‐1 (9–36) Amide, Cleavage Product of GLP‐1 (7–36) Amide, Is a Glucoregulatory Peptide
Elahi, D., Egan, J. M., Shannon, R. P., Meneilly, G. S., Khatri, A., Habener, J. F., & Andersen, D. K. (2008) · Obesity · doi:10.1038/oby.2008.229 · Cited by 104
Qualmann, C., Nauck, M. A., Holst, J. J., �rskov, C., & Creutzfeldt, W. (1995) · Acta Diabetologica · doi:10.1007/bf00581038 · Cited by 101
Self-citationBurcelin, R., Dolci, W., & Thorens, B. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90043-4 · Cited by 101
Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes
Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 103
Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?
Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2003) · Neuropeptides · doi:10.1016/j.npep.2003.09.002 · Cited by 102
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes
Wu, T., Little, T. J., Bound, M. J., Borg, M. J., Zhang, X., Deacon, C. F., Horowitz, M., Jones, K. L., & Rayner, C. K. (2016) · Diabetes Care · doi:10.2337/dc15-2298 · Cited by 100
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Self-citationMuzurović, E. M., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146371 · Cited by 101
Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT
He, Y., Wang, Y., Bullock, J. M., Deacon, C. F., Holst, J. J., Dunning, B. E., Ligueros‐Saylan, M., & Foley, J. E. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006299137 · Cited by 98
Self-citationStructure/Activity Characterization of Glucagon‐Like Peptide‐1
Gallwitz, B., Witt, M., Paetzold, G., Morys‐Wortmann, C., Zimmermann, B. K., Eckart, K., Fölsch, U. R., & Schmidt, W. E. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.1151b.x · Cited by 99
Post-prandial hyperglycemia. post-prandial hyperglycemia and diabetes.
Gin, H., & Rigalleau, V. (2000) · PubMed · Cited by 98
Christensen, M., Calanna, S., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3644 · Cited by 102
Self-citationVolz, A., Göke, R., Lankat-Buttgereit, B., Fehmann, H.-C., Bode, H. P., & Göke, B. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)01006-z · Cited by 96
Yang, W., Pan, C. Y., Tou, C., Zhao, J., & Gause‐Nilsson, I. A. M. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.07.035 · Cited by 96
Gabe, M. B. N., Sparre‐Ulrich, A. H., Pedersen, M. F., Gasbjerg, L. S., Inoue, A., Bräuner‐Osborne, H., Hartmann, B., & ROSENKILDE, M. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.040 · Cited by 95
The Effects of Bariatric Surgery on Islet Function, Insulin Secretion, and Glucose Control
Douros, J. D., Tong, J., & D’Alessio, D. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00183 · Cited by 100
The role of GIP in α-cells and glucagon secretion
EL, K. M., & Campbell, J. E. (2019) · Peptides · doi:10.1016/j.peptides.2019.170213 · Cited by 98
Nogi, Y., Nagashima, M., Terasaki, M., Nohtomi, K., Watanabe, T., & Hirano, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035683 · Cited by 96
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Gault, V. A., Flatt, P. R., & O'Harte, F. P. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01361-5 · Cited by 95
GLP‐1: physiological effects and potential therapeutic applications
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 99
Self-citationEmerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Novikoff, A., O’Brien, S. L., Bernecker, M., Grandl, G., Kleinert, M., Knerr, P. J., Stemmer, K., Klingenspor, M., Zeigerer, A., DiMarchi, R. D., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101181 · Cited by 99
Subaran, S. C., Sauder, M. A., Chai, W., Jahn, L. A., Fowler, D. E., Aylor, K. W., Basu, A., & Liu, Z. (2014) · Clinical Science · doi:10.1042/cs20130708 · Cited by 95
Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus
Vilsbøll, T. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.231 · Cited by 95
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
Nauck, M. A. (1998) · Acta Diabetologica · doi:10.1007/s005920050116 · Cited by 94
Self-citationIncretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Stimulation of incretin secreting cells
Pais, R., Gribble, F. M., & Reimann, F. M. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815618177 · Cited by 105
Incretins and the development of type 2 diabetes
Meier, J. J., & Nauck, M. A. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0034-7 · Cited by 96
Self-citationGlucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 103
Self-citationK-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease
Cho, Y. M., & Kieffer, T. J. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00004-7 · Cited by 98
Hayden, M. R., Patel, K., Habibi, J., Gupta, D., Tekwani, S. S., Whaley‐Connell, A. T., & Sowers, J. R. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00024.x · Cited by 99
Knop, F. K. (2009) · Diabetologia · doi:10.1007/s00125-009-1511-8 · Cited by 95
Aulinger, B. A., Bedorf, A., Kutscherauer, G., de Heer, J., Holst, J. J., Göke, B., & Schirra, J. R. J. (2013) · Diabetes · doi:10.2337/db13-1455 · Cited by 91
Self-citationThe Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes
Gilon, P. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.004 · Cited by 93
Vardarli, I., Arndt, E., Deacon, C. F., Holst, J. J., & Nauck, M. A. (2013) · Diabetes · doi:10.2337/db13-0805 · Cited by 92
Self-citationLynn, F. C., Thompson, S. A., Pospisilik, J. A., Ehses, J. A., Hinke, S. A., Pamir, N., McIntosh, C. H. S., & Pederson, R. A. (2003) · The FASEB Journal · doi:10.1096/fj.02-0243fje · Cited by 91
Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
Flint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0110-x · Cited by 91
Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 92
Yabe, D., Kuroe, A., Lee, S., Watanabe, K., Hyo, T., Hishizawa, M., Kurose, T., Deacon, C. F., Holst, J. J., Hirano, T., et al. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00010.x · Cited by 90
Self-citationJao, C., Hung, C.-C., Tung, Y.-S., Lin, P.-Y., Chen, M., & Hsu, K. (2015) · Biomedicine · doi:10.7603/s40681-015-0014-9 · Cited by 90
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1
Nauck, M. A., & El-Ouaghlidi, A. (2005) · Diabetologia · doi:10.1007/s00125-005-1704-8 · Cited by 90
Self-citationDeane, A. M., Chapman, M. J., Fraser, R. J., Burgstad, C. M., Besanko, L. K., & Horowitz, M. (2009) · Critical Care · doi:10.1186/cc7874 · Cited by 89
Nyholm, B., Walker, M., Gravholt, C. H., Shearing, P. A., Sturis, J., Alberti, K. G. M. M., Holst, J. J., & Schmitz, O. (1999) · Diabetologia · doi:10.1007/s001250051444 · Cited by 91
Self-citationMeier, J. J., Deacon, C. F., Schmidt, W. E., Holst, J. J., & Nauck, M. A. (2007) · Diabetologia · doi:10.1007/s00125-007-0598-z · Cited by 92
Self-citationPathophysiology and pharmacotherapy of gastroparesis: current and future perspectives
Stevens, J. E., Jones, K. L., Rayner, C. K., & Horowitz, M. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.795948 · Cited by 87
Proglucagon processing in islet and intestinal cell lines
Tucker, J. D., Dhanvantari, S., & Brubaker, P. L. (1996) · Regulatory Peptides · doi:10.1016/0167-0115(95)00167-0 · Cited by 84
Gupta, P., Bala, M., Gupta, S. K., Dua, A., Dabur, R., Injeti, E. R., & Mittal, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.029 · Cited by 92
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
Kaku, K., Itayasu, T., Hiroi, S., Hirayama, M., & Seino, Y. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01460.x · Cited by 85
Leveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 84
Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1
Wishart, J. M., Horowitz, M., Morris, H. A., Jones, K. L., & Nauck, M. A. (1998) · Peptides · doi:10.1016/s0196-9781(98)00052-7 · Cited by 85
Self-citationFehmann, H. C., Jiang, J., Schweinfurth, J., Wheeler, M. B., BOYD, A. E., & Göke, B. (1994) · Peptides · doi:10.1016/0196-9781(94)90204-6 · Cited by 84
Meier, J. J., Gallwitz, B., Kask, B., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s220 · Cited by 84
Self-citationMechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids
Sansome, D. J., Xie, C., Veedfald, S., Horowitz, M., Rayner, C. K., & Wu, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13869 · Cited by 84
Pabreja, K., Mohd, M. A., Koole, C., Wootten, D. L., & Furness, S. G. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12313 · Cited by 88
Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly
Gentilcore, D., Bryant, B., Wishart, J. M., Morris, H. A., Horowitz, M., & Jones, K. L. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.05.019 · Cited by 83
Genetically engineered pig models for diabetes research
Wolf, E., Braun-Reichhart, C., Streckel, E., & Renner, S. (2013) · Transgenic Research · doi:10.1007/s11248-013-9755-y · Cited by 84
Lee, J., Cummings, B. P., Martin, E. M., Sharp, J. W., Graham, J. L., Stanhope, K. L., Havel, P. J., & Raybould, H. E. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00345.2011 · Cited by 84
Hare, K. J., Vilsbøll, T., Holst, J. J., & Knop, F. K. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00700.2009 · Cited by 85
Self-citationBiological activity of GLP-1-analogues with N-terminal modifications
Siegel, E. G., Gallwitz, B., Scharf, G., Mentlein, R., Morys‐Wortmann, C., Fölsch, U. R., Schrezenmeir, J., Drescher, K., & Schmidt, W. E. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(98)00155-4 · Cited by 83
Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus
Gallwitz, B. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504060-00005 · Cited by 84
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 86
Adams, R. L., & Broughton, K. S. (2016) · Annals of Nutrition and Metabolism · doi:10.1159/000448665 · Cited by 87
Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes
Deacon, C. F. (2018) · Peptides · doi:10.1016/j.peptides.2017.10.011 · Cited by 85
Hinke, S. A., Manhart, S., Pamir, N., Demuth, H.-U., Gelling, R. W., Pederson, R. A., & McIntosh, C. H. S. (2001) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(01)00181-9 · Cited by 82
Ceriello, A., Esposito, K., Sala, L. L., Pujadas, G., Nigris, V. D., Testa, R., Bucciarelli, L. G., Rondinelli, M., & Genovese, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0140-9 · Cited by 86
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
Evolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S. R. D., & Cherrington, A. D. (2013) · Current Diabetes Reviews · doi:10.2174/1573399811309020007 · Cited by 82
Metadata
- Authors
- Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W.
- Affiliations
- University of Göttingen (DE)
- University of Copenhagen (DK)
- Rigshospitalet (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1993-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 301-307
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC330027
- OpenAlex
- W1969932276
- Cited by
- 1,651
- References
- 41
- Citations by year
- 2026: 45 · 2025: 51 · 2024: 63 · 2023: 63 · 2022: 57 · 2021: 57 · 2020: 50 · 2019: 70 · 2018: 50 · 2017: 49 · 2016: 71 · 2015: 62 · 2014: 75 · 2013: 84 · 2012: 59
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (203/2-1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, GLP-1(7-36)amide, glucose-dependent insulinotropic polypeptide, type 2 diabetes, insulin secretion, C-peptide, glucagon, hyperglycemic clamp, incretin resistance
- MeSH terms
- Insulin Secretion, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glucagon, Glycated Hemoglobin, Humans, Insulin, Kinetics, Male, Middle Aged, Peptide Fragments, Protein Precursors, Reference Values, Time Factors, Glucose Clamp Technique, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
